Astodrimer Gel for Recurrent BV: Symptoms, Recurrence and Follow-Up

A return of odor, an abnormal microscopy result and meeting a trial’s recurrence definition are not interchangeable. Before reading a prevention percentage, check which event the researchers counted.

What counted as BV coming back?

The CDC¹ describes Amsel diagnosis as at least three of four findings: characteristic discharge, clue cells seen under a microscope, vaginal pH above 4.5, and a positive whiff test. Odor alone does not meet that definition.¹

That distinction matters when comparing a study’s clinical endpoint with what someone notices at home. A symptom log can help an appointment; it cannot reproduce microscopy or establish the diagnosis.

What did the astodrimer prevention trial find?

The 2021 trial² randomized 586 women aged 18–45 after successful oral metronidazole treatment. They used astodrimer 1% gel or placebo every second day for 16 weeks. Clinician-defined recurrence occurred in 44.2% versus 54.3%, while reported odor and/or discharge returned in 27.9% versus 40.6%.²

The endpoints and denominators differ. During the 12-week follow-up after treatment stopped, clinician-defined recurrence differences were not statistically significant. Some symptom benefits persisted through eight weeks off treatment. Yeast infections and urinary tract infections were reported more often with astodrimer. Starpharma funded, designed and analyzed the study and prepared the manuscript.²

This prevention study does not establish efficacy after menopause or superiority to antibiotic maintenance.²

How do the Australian instructions limit self-treatment?

The Fleurstat BVgel leaflet currently linked by Aspen Australia, revised February 2023, distinguishes a seven-day treatment course from prevention of recurrent BV. It says to see a doctor before prevention use and not continue beyond 16 weeks without medical supervision.³

For treatment, it calls for review if symptoms persist after seven days or recur within two weeks. It also directs people who are pregnant, planning pregnancy, breastfeeding or diabetic to a doctor. Avoid combining it with vaginal products containing polyquaterniums; these can be incompatible with astodrimer.³

These are Australian product instructions. Do not assume that an online listing establishes the same licensed use, formulation or supply arrangements where you live. Take the package or leaflet to the pharmacist rather than assembling a regimen from the trial schedule.

What should a recurrence appointment cover?

The CDC’s¹ 2021 guidance advises returning for evaluation when symptoms recur and describes limited evidence for optimal recurrent-BV management. It mentions favorable astodrimer prevention findings separately from its standard recommended antibiotic regimens.¹

Ask what confirmed the earlier episode, what confirmed clearance and how a new episode will be assessed. Record dates of treatment, symptom return, bleeding and any new vaginal products. A treatment that reduces odor does not automatically answer whether BV has returned or whether another condition needs attention.

“When BV Comes Back” in Down There, Decoded distinguishes recurrence measurements from symptoms and places longer suppression within a clinician-led plan. Our recurrent BV guide covers the broader recurrence discussion.